Starpharm - A turnaround pharma stock

More
29 Jul 2013 19:39 #15408 by Oceangrace
Cos i followed the same Guru in shareinvestor :P hahaha

h0ly0wl wrote: gangho you are free2nap in shareinvestor right? :)

Please Log in or Create an account to join the conversation.

More
29 Jul 2013 19:39 #15409 by h0ly0wl
great call as usual in CI, too bad i no more ammo liao.. hahaha
The following user(s) said Thank You: Susie

Please Log in or Create an account to join the conversation.

More
29 Jul 2013 19:42 #15412 by h0ly0wl

Oceangrace wrote: Cos i followed the same Guru in shareinvestor :P hahaha

h0ly0wl wrote: gangho you are free2nap in shareinvestor right? :)


Their style are similar. lol

Please Log in or Create an account to join the conversation.

More
30 Jul 2013 13:39 #15418 by gangho

h0ly0wl wrote:

Oceangrace wrote: Cos i followed the same Guru in shareinvestor :P hahaha

h0ly0wl wrote: gangho you are free2nap in shareinvestor right? :)


Their style are similar. lol

Holyowl, you have very sharp eyes to see similar style. Peifu peifu. still learning how to excel in selecting right stocks and do share some tips too....

Please Log in or Create an account to join the conversation.

More
02 Aug 2013 04:54 #15456 by gangho
Interesting announcement on clinical rpt using Starpharm's manufactured drug, [甲钴胺,由海南斯达制药有限公司生产)每日1500μg] to treat diabetes.

Is this one of the Cat 1 drugs that Starpharm mentioned in its 2012 annual rpt??


www.yixue360.com/StaticPage/S86/137251411191024.html

凯时与弥可保联合用药治疗糖尿病周围神经病变的临床疗效观察




发表时间:2013-7-25 14:11:19来源:创新医学网医学编辑部









  作者:张晓梅,张大勃 作者单位:山西省晋城煤业集团古书院矿医院,048600

  【摘要】目的 观察凯时(前列腺素E1)与弥可保(甲钴胺)大剂量联合应用治疗糖尿病周围神经病变的疗效。方法 102例糖尿病患者中选取合并周围神经病变的患者48人,随机分为对照组和治疗组,对照组24例,单用弥可保1500μg,加于生理盐水100Ml每日1次静点,连用2周;治疗组24例,在对照组基础上,加凯时 20μg于生理盐水100Ml每日1次静点,共2周。结果 治疗组有效率达95.8%,明显高于对照组54.2%(P<0.05)。结论 凯时与弥可保联合用药治疗糖尿病周围神经病变可明显提高糖尿病周围神经病变的治疗效果。

  【关键词】糖尿病周围神经病变,弥可保,凯时

  随着我国社会经济的发展,人们的生活水平普遍提高,患糖尿病的人数逐年增加。据统计,全国已有2400万糖尿病患者,其中40岁以上的又占绝大多数。此外,糖尿病所引起的失明,肾功能衰竭,心脑血管疾病,下肢坏疽,分别是正常人的25、17、2-3、20-30倍[1],糖尿病已成为严重威胁人类健康的慢性流行性疾病。

  糖尿病周围神经病变(DPN)是糖尿病最常见的慢性并发症之一,1型和2型糖尿病的糖尿病周围神经病变(DPN)发病情况一致。由于糖尿病周围神经病变(DPN)的受累部位不同,神经病变的临床表现多样,可累及感觉神经、运动神经及植物神经,临床症状多表现为持续性疼痛、麻木、感觉减退及自主神经功能障碍,给患者带来极大的痛苦,但目前尚缺乏疗效显著的治疗手段。由于糖尿病周围神经病变发病机制复杂,有多种病理因素参加,作用于多个环节,因而针对某个病理环节的单独用药取得的临床疗效不能令人满意。我院应用凯时与弥可保联合治疗糖尿病周围神经病变,临床疗效满意,现总结如下。

  1 资料与方法

  1.1 一般资料 选择2008年6月~2010年5月在我院门诊及住院病人102例中选取合并周围神经病变的患者48人(均符合1997年ADA糖尿病诊断标准),随机分为对照组和治疗组,每组24例进行观察。治疗组24例,男21例,女3例,年龄47~85岁,平均年龄67.4岁,病程6~27年。对照组24例,男22例,女2例,年龄54~82岁,平均年龄69.9岁,病程8~22年。两组患者均有不同程度的以下临床症状:(1)有对称性肢体麻木、疼痛、感觉异常、偶有蚁走感、热灼感;(2)四肢浅感觉减退,尤以双下肢为甚;(3)排除其它病因引起的周围神经病变。所有病例均给予科学运动、饮食控制、降血糖等综合治疗,血糖控制在空腹<7.0MMol/L餐后2小时<10.0MMol/L。

  1.2 方法 对照组24例,单用弥可保(甲钴胺,由海南斯达制药有限公司生产)每日1500μg(常规量500μg)加于生理盐水100Ml,每日1次静点,连用2周;治疗组24例,在对照组基础上,加凯时(前列腺素E1,由北京泰得制药有限公司生产)20μg(常规量5~10μg)于生理盐水100Ml每日1次静点,共2周。全部病例均在治疗前及治疗后测晨起空腹血糖、血生化、肝肾功能、血常规,记录症状(麻木、疼痛、感觉异常)及体征(腱反射、深浅反射)。

  1.3 疗效判断标准 显效:自觉症状明显好转,跟膝腱反射明显好转、恢复,或深浅感觉完全恢复正常。有效:自觉症状改善,跟膝腱反射有所好转,深浅感觉有所改善。无效:症状无减轻,腱反射、深浅感觉无改善。

  2 结果

  两组临床疗效比较、治疗组优于对照组,差异有非常显著性(P<0.05),见表1。两组治疗前后空腹血糖、餐后2小时血糖、肝功能、肾功能均无显著变化,两组未见不良反应。

  表1 两组患者疗效对比

Please Log in or Create an account to join the conversation.

More
14 Aug 2013 01:32 #15634 by Oceangrace
Understand there was a catalyst report by UOB. Anyone knows the link?

Please Log in or Create an account to join the conversation.

Share Prices

Counter NameLastChange
AEM Holdings1.9300.030
AusGroup0.0330.002
Avi-Tech Electronics0.4200.005
Best World Int.1.360-
CEI0.955-
China Sunsine0.5100.010
CNMC GoldMine0.245-
CSE Global0.535-
Eagle HTrust USD0.515-0.005
Food Empire0.615-
Golden Energy0.159-
GSS Energy0.0860.002
ISDN Holdings0.2200.005
ISOTeam0.245-
JB Foods0.655-
KSH Holdings0.4400.010
Miyoshi0.030-
Moya Asia0.065-0.001
Nordic Group0.280-
Oxley Holdings0.350-0.005
Procurri0.475-0.005
REX International0.1860.007
Riverstone0.950-0.020
Roxy-Pacific0.4000.005
Sing Holdings0.3900.005
SingMedical0.295-
Straco Corp.0.6750.005
Sunningdale Tech1.3300.050
Sunpower Group0.5900.015
The Trendlines0.087-
Tiong Seng0.200-
Uni-Asia Group0.745-
Yangzijiang Shipbldg1.1300.040

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 670 guests and no members online